# Proton Pump Inhibitor Use Exceeding the U.S. Food and Drug Administration Approved Treatment Duration for Patients With Peptic Ulcer Disease: A Retrospective Cohort Study

## TL;DR

This study finds that many patients with peptic ulcer disease are prescribed proton pump inhibitors beyond the recommended eight-week duration, often due to complex health factors.

## Contribution

The study identifies specific patient and healthcare factors linked to prolonged PPI use, offering insights for deprescribing strategies.

## Key findings

- 35% of patients had PPI prescriptions exceeding the approved duration for a median of 346 days.
- Inpatient diagnosis, NSAID use, anticoagulant use, and moderate frailty were strongly associated with prolonged PPI prescriptions.
- Inpatient diagnosis had the highest population-attributable fraction for PPI overuse.

## Abstract

Proton‐pump inhibitors (PPIs) are effective in treating peptic ulcer disease (PUD), but they are often prescribed beyond the approved duration. Because PPIs are associated with adverse effects, there is a need for effective stewardship.

To identify the frequency of and healthcare factors associated with PPI prescriptions exceeding the approved eight‐week treatment duration for PUD.

We conducted a retrospective cohort study of patients diagnosed with acute PUD without other indications for PPI use using data from the Veterans Health Administration in the United States. Exposures were patient, provider, and facility factors that could influence PPI prescribing. The outcome was time to a filled PPI prescription exceeding the approved treatment duration for PUD. Associations were assessed using a multivariable time‐to‐recurrent‐event model to calculate adjusted hazard ratios (aHR) and population‐attributable fractions. Patients who developed indications for long‐term PPI use were censored.

We identified 7708 patients with PUD who met eligibility criteria and received PUD treatment (median age 79 [IQR 71–85], 7% female). Thirty‐five percent had PPI prescriptions exceeding the approved duration for a median of 346 days (IQR 165–643) of overuse. On the patient level, inpatient PUD diagnosis (aHR 1.32, 95% CI 1.25–1.39), use of nonsteroidal anti‐inflammatory drugs (NSAIDs) (aHR 1.26, 95% CI 1.18–1.34), use of anticoagulants (aHR 1.25, 95% CI 1.13–1.38), and moderate frailty (1.15, 95% CI 1.06–1.26) had the strongest associations with filled PPI prescriptions exceeding the approved duration. On the health‐system level, inpatient PUD diagnosis had the highest peak population attributable fraction at 0.26, followed by NSAIDs and anticoagulants at 0.18.

Markers of patient complexity and medication use not meeting gastroprotection guidelines are associated with inappropriate PPI persistence among patients with PUD. These data may inform future targeted PPI deprescribing programs.